Skip to main content
Top
Published in: Molecular Cancer 1/2012

Open Access 01-12-2012 | Research

Importance of glycolysis and oxidative phosphorylation in advanced melanoma

Authors: Jonhan Ho, Michelle Barbi de Moura, Yan Lin, Garret Vincent, Stephen Thorne, Lyn M Duncan, Lin Hui-Min, John M Kirkwood, Dorothea Becker, Bennett Van Houten, Stergios J Moschos

Published in: Molecular Cancer | Issue 1/2012

Login to get access

Abstract

Serum lactate dehydrogenase (LDH) is a prognostic factor for patients with stage IV melanoma. To gain insights into the biology underlying this prognostic factor, we analyzed total serum LDH, serum LDH isoenzymes, and serum lactate in up to 49 patients with metastatic melanoma. Our data demonstrate that high serum LDH is associated with a significant increase in LDH isoenzymes 3 and 4, and a decrease in LDH isoenzymes 1 and 2. Since LDH isoenzymes play a role in both glycolysis and oxidative phosphorylation (OXPHOS), we subsequently determined using tissue microarray (TMA) analysis that the levels of proteins associated with mitochondrial function, lactate metabolism, and regulators of glycolysis were all elevated in advanced melanomas compared with nevic melanocytes. To investigate whether in advanced melanoma, the glycolysis and OXPHOS pathways might be linked, we determined expression of the monocarboxylate transporters (MCT) 1 and 4. Analysis of a nevus-to-melanoma progression TMA revealed that MCT4, and to a lesser extend MCT1, were elevated with progression to advanced melanoma. Further analysis of human melanoma specimens using the Seahorse XF24 extracellular flux analyzer indicated that metastatic melanoma tumors derived a large fraction of energy from OXPHOS. Taken together, these findings suggest that in stage IV melanomas with normal serum LDH, glycolysis and OXPHOS may provide metabolic symbiosis within the same tumor, whereas in stage IV melanomas with high serum LDH glycolysis is the principle source of energy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013CrossRefPubMed Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013CrossRefPubMed
2.
go back to reference Warburg O: On the origin of cancer cells. Science. 1956, 123: 309-314. 10.1126/science.123.3191.309CrossRefPubMed Warburg O: On the origin of cancer cells. Science. 1956, 123: 309-314. 10.1126/science.123.3191.309CrossRefPubMed
3.
go back to reference Elia U, Flescher E: Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment. Curr Pharm Biotechnol. 2012, Jun 1. [Epub ahead of print]. Elia U, Flescher E: Combined Chemotherapy or Biotherapy with Jasmonates: Targeting Energy Metabolism for Cancer Treatment. Curr Pharm Biotechnol. 2012, Jun 1. [Epub ahead of print].
4.
go back to reference Rodríguez-Enríquez S, Gallardo-Pérez JC, Marín-Hernández A, Moreno-Sánchez R: The Warburg Hypothesis and the ATP Supply In Cancer Cells Is Oxidative Phosphorylation impaired in malignant neoplasias?. Curr Pharm Biotechnol. 2012, Jun 1. [Epub ahead of print]. Rodríguez-Enríquez S, Gallardo-Pérez JC, Marín-Hernández A, Moreno-Sánchez R: The Warburg Hypothesis and the ATP Supply In Cancer Cells Is Oxidative Phosphorylation impaired in malignant neoplasias?. Curr Pharm Biotechnol. 2012, Jun 1. [Epub ahead of print].
5.
go back to reference Barbi de Moura M, Vincent G, Fayewicz SL, Bateman N, Hood BL, Sun M, Suhan J, Duensing S, Yin Y, Sander C: Mitochondrial Respiration - an Important Therapeutic Target in Melanoma. PLoS One. 2012, 7 (8): e40690- 10.1371/journal.pone.0040690PubMedCentralCrossRefPubMed Barbi de Moura M, Vincent G, Fayewicz SL, Bateman N, Hood BL, Sun M, Suhan J, Duensing S, Yin Y, Sander C: Mitochondrial Respiration - an Important Therapeutic Target in Melanoma. PLoS One. 2012, 7 (8): e40690- 10.1371/journal.pone.0040690PubMedCentralCrossRefPubMed
6.
go back to reference Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW: Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem. 2011, 286: 42626-42634. 10.1074/jbc.M111.282046PubMedCentralCrossRefPubMed Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW: Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem. 2011, 286: 42626-42634. 10.1074/jbc.M111.282046PubMedCentralCrossRefPubMed
7.
go back to reference Qin JZ, Xin H, Nickoloff BJ: Targeting glutamine metabolism sensitizes melanoma cells to TRAIL-induced death. Biochem Biophys Res Commun. 2010, 398: 146-152. 10.1016/j.bbrc.2010.06.057CrossRefPubMed Qin JZ, Xin H, Nickoloff BJ: Targeting glutamine metabolism sensitizes melanoma cells to TRAIL-induced death. Biochem Biophys Res Commun. 2010, 398: 146-152. 10.1016/j.bbrc.2010.06.057CrossRefPubMed
8.
go back to reference Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, Vaupel P: Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res. 1989, 49 (14): 3759-3764.PubMed Kallinowski F, Schlenger KH, Runkel S, Kloes M, Stohrer M, Okunieff P, Vaupel P: Blood flow, metabolism, cellular microenvironment, and growth rate of human tumor xenografts. Cancer Res. 1989, 49 (14): 3759-3764.PubMed
9.
go back to reference Nakajima EC, Van Houten B: Metabolic symbiosis in cancer: Refocusing the Warburg lens. Mol Carcinog. 2012, 10.1002/mc.21863. Jan 6: [Epub ahead of print]. Nakajima EC, Van Houten B: Metabolic symbiosis in cancer: Refocusing the Warburg lens. Mol Carcinog. 2012, 10.1002/mc.21863. Jan 6: [Epub ahead of print].
10.
go back to reference Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008, 118: 3930-3942.PubMedCentralPubMed Sonveaux P, Vegran F, Schroeder T, Wergin MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C, Jordan BF: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. 2008, 118: 3930-3942.PubMedCentralPubMed
11.
go back to reference Manola J, Atkins M, Ibrahim J, Kirkwood J: Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000, 18: 3782-3793.PubMed Manola J, Atkins M, Ibrahim J, Kirkwood J: Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials. J Clin Oncol. 2000, 18: 3782-3793.PubMed
12.
go back to reference Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002, 20: 125-133. 10.1200/JCO.20.1.125CrossRefPubMed Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R: Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002, 20: 125-133. 10.1200/JCO.20.1.125CrossRefPubMed
13.
go back to reference Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006, 24: 4738-4745. 10.1200/JCO.2006.06.0483CrossRefPubMed Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P: Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006, 24: 4738-4745. 10.1200/JCO.2006.06.0483CrossRefPubMed
14.
go back to reference Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D: BEAM: a randomized phase ii study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012, 30: 34-41. 10.1200/JCO.2011.34.6270CrossRefPubMed Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D: BEAM: a randomized phase ii study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012, 30: 34-41. 10.1200/JCO.2011.34.6270CrossRefPubMed
15.
go back to reference Hauschild A, Eggermont AM, Jacobson E, O'Day SJ: Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (LBA9012) [abstract]. J Clin Oncol. 2009, 27: 18s-10.1200/JCO.2009.22.4626. 10.1200/JCO.2009.22.4626CrossRef Hauschild A, Eggermont AM, Jacobson E, O'Day SJ: Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (LBA9012) [abstract]. J Clin Oncol. 2009, 27: 18s-10.1200/JCO.2009.22.4626. 10.1200/JCO.2009.22.4626CrossRef
16.
go back to reference Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, Jonneaux A, Marchetti P, Kluza J, Rao PE: Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS One. 2012, 7: e29798- 10.1371/journal.pone.0029798PubMedCentralCrossRefPubMed Blackman RK, Cheung-Ong K, Gebbia M, Proia DA, He S, Kepros J, Jonneaux A, Marchetti P, Kluza J, Rao PE: Mitochondrial electron transport is the cellular target of the oncology drug elesclomol. PLoS One. 2012, 7: e29798- 10.1371/journal.pone.0029798PubMedCentralCrossRefPubMed
17.
go back to reference Moschos SJ, Dodd NR, Jukic DM, Fayewicz SL, Wang X, Becker D: Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation. Cancer Biol Ther. 2009, 8: 1815-1825. 10.4161/cbt.8.19.9435CrossRefPubMed Moschos SJ, Dodd NR, Jukic DM, Fayewicz SL, Wang X, Becker D: Suppressing the high-level expression and function of ATM in advanced-stage melanomas does not sensitize the cells to ionizing radiation. Cancer Biol Ther. 2009, 8: 1815-1825. 10.4161/cbt.8.19.9435CrossRefPubMed
18.
go back to reference Nazarian RM, Prieto VG, Elder DE, Duncan LM: Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol. 2010, 37 (Suppl 1): 41-47.CrossRefPubMed Nazarian RM, Prieto VG, Elder DE, Duncan LM: Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol. 2010, 37 (Suppl 1): 41-47.CrossRefPubMed
19.
go back to reference Moschos SJ, Jukic DM, Athanassiou C, Bhargava R, Dacic S, Wang X, Kuan SF, Fayewicz SL, Galambos C, Acquafondata M: Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum Pathol. 2010, 41: 1286-1298. 10.1016/j.humpath.2010.02.007CrossRefPubMed Moschos SJ, Jukic DM, Athanassiou C, Bhargava R, Dacic S, Wang X, Kuan SF, Fayewicz SL, Galambos C, Acquafondata M: Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum Pathol. 2010, 41: 1286-1298. 10.1016/j.humpath.2010.02.007CrossRefPubMed
20.
go back to reference Detre S, Saclani Jotti G, Dowsett M: A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995, 48: 876-878. 10.1136/jcp.48.9.876PubMedCentralCrossRefPubMed Detre S, Saclani Jotti G, Dowsett M: A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995, 48: 876-878. 10.1136/jcp.48.9.876PubMedCentralCrossRefPubMed
21.
go back to reference Hsu MY, Kohler MM, Barolia L, Bondar RJ: Separation of five isoenzymes of serum lactate dehydrogenase by discontinuous gradient elution from a miniature ion-exchange column. Clin Chem. 1979, 25: 1453-1458.PubMed Hsu MY, Kohler MM, Barolia L, Bondar RJ: Separation of five isoenzymes of serum lactate dehydrogenase by discontinuous gradient elution from a miniature ion-exchange column. Clin Chem. 1979, 25: 1453-1458.PubMed
22.
go back to reference Qian W, Van Houten B: Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods. 2010, 51: 452-457. 10.1016/j.ymeth.2010.03.006CrossRefPubMed Qian W, Van Houten B: Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods. 2010, 51: 452-457. 10.1016/j.ymeth.2010.03.006CrossRefPubMed
23.
go back to reference Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P: Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol. 2011, 2: 49-PubMedCentralCrossRefPubMed Porporato PE, Dhup S, Dadhich RK, Copetti T, Sonveaux P: Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Front Pharmacol. 2011, 2: 49-PubMedCentralCrossRefPubMed
24.
go back to reference Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996, 271: 32529-32537. 10.1074/jbc.271.51.32529CrossRefPubMed Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, Giallongo A: Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem. 1996, 271: 32529-32537. 10.1074/jbc.271.51.32529CrossRefPubMed
25.
go back to reference Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, Birner P, Pehamberger H: Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol. 2009, 34: e962-e964. 10.1111/j.1365-2230.2009.03706.xCrossRefPubMed Valencak J, Kittler H, Schmid K, Schreiber M, Raderer M, Gonzalez-Inchaurraga M, Birner P, Pehamberger H: Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. Clin Exp Dermatol. 2009, 34: e962-e964. 10.1111/j.1365-2230.2009.03706.xCrossRefPubMed
26.
go back to reference Yusenko MV, Ruppert T, Kovacs G: Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis. Int J Biol Sci. 2010, 6: 213-224.PubMedCentralCrossRefPubMed Yusenko MV, Ruppert T, Kovacs G: Analysis of differentially expressed mitochondrial proteins in chromophobe renal cell carcinomas and renal oncocytomas by 2-D gel electrophoresis. Int J Biol Sci. 2010, 6: 213-224.PubMedCentralCrossRefPubMed
27.
go back to reference Neri D, Supuran CT: Interfering with pH regulation in tumours as a therapeutic strategy. Nature Rev Drug Discov. 2011, 10: 767-777. 10.1038/nrd3554.CrossRef Neri D, Supuran CT: Interfering with pH regulation in tumours as a therapeutic strategy. Nature Rev Drug Discov. 2011, 10: 767-777. 10.1038/nrd3554.CrossRef
28.
go back to reference Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB, Owen CS: Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther. 2002, 1: 617-628.PubMed Wahl ML, Owen JA, Burd R, Herlands RA, Nogami SS, Rodeck U, Berd D, Leeper DB, Owen CS: Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther. 2002, 1: 617-628.PubMed
29.
go back to reference Finck SJ, Giuliano AE, Morton DL: LDH and melanoma. Cancer. 1983, 51: 840-843. 10.1002/1097-0142(19830301)51:5<840::AID-CNCR2820510516>3.0.CO;2-7CrossRefPubMed Finck SJ, Giuliano AE, Morton DL: LDH and melanoma. Cancer. 1983, 51: 840-843. 10.1002/1097-0142(19830301)51:5<840::AID-CNCR2820510516>3.0.CO;2-7CrossRefPubMed
30.
go back to reference Khurana P, Tyagi N, Salahuddin A, Tyagi SP: Serum lactate dehydrogenase isoenzymes in breast tumours. Indian J Pathol Microbiol. 1990, 33: 355-359.PubMed Khurana P, Tyagi N, Salahuddin A, Tyagi SP: Serum lactate dehydrogenase isoenzymes in breast tumours. Indian J Pathol Microbiol. 1990, 33: 355-359.PubMed
31.
go back to reference Giannoulaki EE, Kalpaxis DL, Tentas C, Fessas P: Lactate dehydrogenase isoenzyme pattern in sera of patients with malignant diseases. Clin Chem. 1989, 35: 396-399.PubMed Giannoulaki EE, Kalpaxis DL, Tentas C, Fessas P: Lactate dehydrogenase isoenzyme pattern in sera of patients with malignant diseases. Clin Chem. 1989, 35: 396-399.PubMed
32.
go back to reference Xu K, Mao X, Mehta M, Cui J, Zhang C, Xu Y: A Comparative Study of Gene-Expression Data of Basal Cell Carcinoma and Melanoma Reveals New Insights about the Two Cancers. PLoS One. 2012, 7: e30750- 10.1371/journal.pone.0030750PubMedCentralCrossRefPubMed Xu K, Mao X, Mehta M, Cui J, Zhang C, Xu Y: A Comparative Study of Gene-Expression Data of Basal Cell Carcinoma and Melanoma Reveals New Insights about the Two Cancers. PLoS One. 2012, 7: e30750- 10.1371/journal.pone.0030750PubMedCentralCrossRefPubMed
33.
go back to reference Berridge MV, Tan AS: Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res. 2010, 13 (2–3): 139-141.CrossRefPubMed Berridge MV, Tan AS: Effects of mitochondrial gene deletion on tumorigenicity of metastatic melanoma: reassessing the Warburg effect. Rejuvenation Res. 2010, 13 (2–3): 139-141.CrossRefPubMed
34.
go back to reference Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW: Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res. 2012, 25: 375-383. 10.1111/j.1755-148X.2012.00989.xPubMedCentralCrossRefPubMed Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW: Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res. 2012, 25: 375-383. 10.1111/j.1755-148X.2012.00989.xPubMedCentralCrossRefPubMed
35.
go back to reference Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S: The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 2000, 350 (Pt 1): 219-227.PubMedCentralCrossRefPubMed Dimmer KS, Friedrich B, Lang F, Deitmer JW, Broer S: The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J. 2000, 350 (Pt 1): 219-227.PubMedCentralCrossRefPubMed
36.
go back to reference Ullah MS, Davies AJ, Halestrap AP: The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem. 2006, 281: 9030-9037.CrossRefPubMed Ullah MS, Davies AJ, Halestrap AP: The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem. 2006, 281: 9030-9037.CrossRefPubMed
37.
go back to reference Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL: HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007, 129: 111-122. 10.1016/j.cell.2007.01.047CrossRefPubMed Fukuda R, Zhang H, Kim JW, Shimoda L, Dang CV, Semenza GL: HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell. 2007, 129: 111-122. 10.1016/j.cell.2007.01.047CrossRefPubMed
38.
go back to reference de Moura MB, dos Santos LS, Van Houten B: Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen. 2010, 51: 391-405.PubMed de Moura MB, dos Santos LS, Van Houten B: Mitochondrial dysfunction in neurodegenerative diseases and cancer. Environ Mol Mutagen. 2010, 51: 391-405.PubMed
39.
go back to reference Mazure NM, Brahimi-Horn MC, Pouyssegur J: Hypoxic mitochondria: accomplices in resistance. Bull Cancer. 2011, 98: 40-46.PubMed Mazure NM, Brahimi-Horn MC, Pouyssegur J: Hypoxic mitochondria: accomplices in resistance. Bull Cancer. 2011, 98: 40-46.PubMed
40.
go back to reference Hendifar AE, Chawla SP, Quon D, Chua VS, Fernandez L, Nagre S, Okunnu M, Chmielowski B, Singh AS, Akmaev S: Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity [abstr 3015]. J Clin Oncol. 2012, 27: Hendifar AE, Chawla SP, Quon D, Chua VS, Fernandez L, Nagre S, Okunnu M, Chmielowski B, Singh AS, Akmaev S: Phase I study of BPM 31510 in advanced solid tumors: Updated analysis of a novel treatment with promising activity [abstr 3015]. J Clin Oncol. 2012, 27:
41.
go back to reference Le Floch R, Chiche J, Marchiq I, Naiken T, Ilk K, Murray CM, Critchlow SE, Roux D, Simon MP, Pouyssegur J: CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci USA. 2011, 108: 16663-16668. 10.1073/pnas.1106123108PubMedCentralCrossRefPubMed Le Floch R, Chiche J, Marchiq I, Naiken T, Ilk K, Murray CM, Critchlow SE, Roux D, Simon MP, Pouyssegur J: CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci USA. 2011, 108: 16663-16668. 10.1073/pnas.1106123108PubMedCentralCrossRefPubMed
Metadata
Title
Importance of glycolysis and oxidative phosphorylation in advanced melanoma
Authors
Jonhan Ho
Michelle Barbi de Moura
Yan Lin
Garret Vincent
Stephen Thorne
Lyn M Duncan
Lin Hui-Min
John M Kirkwood
Dorothea Becker
Bennett Van Houten
Stergios J Moschos
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2012
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-11-76

Other articles of this Issue 1/2012

Molecular Cancer 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine